» Articles » PMID: 23254286

LECT2 Protects Mice Against Bacterial Sepsis by Activating Macrophages Via the CD209a Receptor

Overview
Journal J Exp Med
Date 2012 Dec 21
PMID 23254286
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Leukocyte cell-derived chemotaxin 2 (LECT2) is a multifunctional cytokine and reduced plasma levels were found in patients with sepsis. However, precise functions and mechanisms of LECT2 remain unclear. The aim of the present study was to determine the role of LECT2 in modulating immune responses using mouse sepsis models. We found that LECT2 treatment improved outcome in mice with bacterial sepsis. Macrophages (MΦ), but not polymorphonuclear neutrophils, mediated the beneficial effect of LECT2 on bacterial sepsis. LECT2 treatment could alter gene expression and enhance phagocytosis and bacterial killing of MΦ in vitro. CD209a was identified to specifically interact with LECT2 and mediate LECT2-induced MΦ activation. CD209a-expressing MΦ was further confirmed to mediate the effect of LECT2 on sepsis in vivo. Our data demonstrate that LECT2 improves protective immunity in bacterial sepsis, possibly as a result of enhanced MΦ functions via the CD209a receptor. The modulation of MΦ functions by LECT2 may serve as a novel potential treatment for sepsis.

Citing Articles

Leukocyte cell-derived chemotaxin 2 (LECT2) regulates liver ischemia-reperfusion injury.

Dong M, Xie Y, Tang Z, Zhao X, Lin F, Zhang G Liver Res. 2025; 8(3):165-171.

PMID: 39957753 PMC: 11771270. DOI: 10.1016/j.livres.2024.09.004.


Role of LECT2 in exacerbating atopic dermatitis: insight from and models via NF-κB signaling pathway.

Liu Z, Jiang X, Zhao K, Ruan H, Ma Y, Ma Y Front Immunol. 2024; 15:1439367.

PMID: 39206203 PMC: 11349537. DOI: 10.3389/fimmu.2024.1439367.


Discovery of Ll-CATH: a novel cathelicidin from the Chong'an Moustache Toad (Leptobrachium liui) with antibacterial and immunomodulatory activity.

Chen J, Zhang C, Wang Y, Zhang L, Seah R, Ma L BMC Vet Res. 2024; 20(1):343.

PMID: 39095814 PMC: 11295328. DOI: 10.1186/s12917-024-04202-9.


Global research trends and hotspots for leukocyte cell-derived chemotaxin-2 from the past to 2023: a combined bibliometric review.

Liu W, Wang Q, Yeerlan J, Yan Y, Xu L, Jia C Front Immunol. 2024; 15:1413466.

PMID: 38881894 PMC: 11176436. DOI: 10.3389/fimmu.2024.1413466.


Elevated serum levels of leukocyte cell-derived chemotaxin 2 are associated with the prevalence of metabolic syndrome.

Zheng X, Lu J, Xiang S, Zou P, Chen H, Liu J Acta Diabetol. 2024; 61(5):643-655.

PMID: 38383671 DOI: 10.1007/s00592-024-02242-z.


References
1.
Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma B . Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2011; 142(3):505-512.e1. DOI: 10.1053/j.gastro.2011.11.027. View

2.
Gros P, Milder F, Janssen B . Complement driven by conformational changes. Nat Rev Immunol. 2007; 8(1):48-58. DOI: 10.1038/nri2231. View

3.
Ong H, Tan P, Wang S, Hian Low D, Ooi L, Hui K . The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target. Cancer Gene Ther. 2011; 18(6):399-406. DOI: 10.1038/cgt.2011.5. View

4.
Kang Y, Yamazaki S, Iyoda T, Pack M, Bruening S, Kim J . SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int Immunol. 2003; 15(2):177-86. DOI: 10.1093/intimm/dxg019. View

5.
Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. View